JPH026335B2 - - Google Patents
Info
- Publication number
- JPH026335B2 JPH026335B2 JP57050540A JP5054082A JPH026335B2 JP H026335 B2 JPH026335 B2 JP H026335B2 JP 57050540 A JP57050540 A JP 57050540A JP 5054082 A JP5054082 A JP 5054082A JP H026335 B2 JPH026335 B2 JP H026335B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- electrolytes
- glucose
- sodium
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003792 electrolyte Substances 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- -1 organic acid salt Chemical class 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 239000003978 infusion fluid Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- 235000021476 total parenteral nutrition Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000004040 coloring Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 5
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001540 sodium lactate Substances 0.000 description 4
- 235000011088 sodium lactate Nutrition 0.000 description 4
- 229940005581 sodium lactate Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940001447 lactate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は一剤のなかにブドウ糖、アミノ酸およ
び電解質を含有し、しかも安全性に優れた輸液の
製造法に関する。
完全静脈栄養として投与される輸液中の主要成
分であるブドウ糖、アミノ酸および電解質におい
て、アミノ酸としてはイソロイシン、ロイシン、
メチオニン、フエニルアラニン、トレオニン、バ
リン、トリプトフアン、リジン、アルギニン、ヒ
スチジンの如き必須アミノ酸の外にアスパラギン
酸、グルタミン酸、アラニン、シスチン、アミノ
酢酸、プロリン、セリン、チロジン等が適宜配合
され、上記電解質としてはカリウム、ナトリウ
ム、マグネシウム、カルシウム、リン、クロール
の各イオンを供給する塩が使用されるが、一般的
には、塩化物、硫酸塩、リン酸塩および有機酸塩
の形で用いられる。これらの主要成分すなわちブ
ドウ糖、アミノ酸および電解質を共に含む輸液製
剤は、酸合に伴う安定性の問題、例えば着色する
傾向があるためいまだに製造されておらず、現在
のところは別個に製造されたブドウ糖・電解質製
剤およびアミノ酸製剤が使用時混合されて患者に
投与されている。この二つの製剤を単一の製剤に
合一することは使用時配合の手数を軽減し、また
菌汚染の可能性を減らすなどの有田性がみこまれ
るのであるが、合一製剤の最大の問題は、水溶液
中で糖とアミノ酸との間に褐変反応(メイラード
反応)がおこるために製剤が着色しやすく、耐滅
菌性、保存性に劣ることである。
本発明者はブドウ糖、アミノ酸および電解質を
含む水溶液の上述した着色の防止について種々検
討を加えた結果、後述する如く着色にはPH依存性
があり、PHが高くなるほど着色しやすくなるこ
と、および有機酸塩の種類によつて着色に大きな
差異が生ずること、そして有機酸塩のなかでは乳
酸塩が着色を最も少なくすることを見出して本発
明を完成した。
即ち、本発明はブドウ糖、アミノ酸および電解
質を含む完全静脈栄養に使用する輸液であつて、
電解質として有機酸塩、または有機酸塩と無機酸
塩の混合物を用いた輸液において、有機酸塩とし
て乳酸塩を使用し、乳酸および/または鉱酸でPH
を4.5〜5.5に調整することからなる輸液の製造法
にある。
以下に本発明を詳細に説明する。
下表1に示す3種の組成の水溶液をアンプル中
窒素置換下に溶封し、100℃で30分または60分加
熱すると、組成AおよびBでは液は黄〜褐色に着
色し、その強さは400nmの吸光度で表わすこと
ができる。アミノ酸と電解質を含むがブドウ糖が
共存しない組成Cでは、加熱後殆ど着色しない
が、ブドウ糖とアミノ酸が共存する組成Aおよび
Bで着色がおこり特に電解質が加わつたAはBに
くらべて更に著しく着色した。
The present invention relates to a method for producing an infusion solution that contains glucose, amino acids, and electrolytes in one drug and is highly safe. Glucose, amino acids, and electrolytes, which are the main components of infusions administered as complete parenteral nutrition, include isoleucine, leucine,
In addition to essential amino acids such as methionine, phenylalanine, threonine, valine, tryptophan, lysine, arginine, and histidine, aspartic acid, glutamic acid, alanine, cystine, aminoacetic acid, proline, serine, tyrosine, etc. are appropriately blended as the electrolyte. Salts that supply potassium, sodium, magnesium, calcium, phosphorus, and chloride ions are used, but they are generally used in the form of chlorides, sulfates, phosphates, and organic acid salts. Infusion formulations that contain these key ingredients together, glucose, amino acids, and electrolytes, have not yet been manufactured due to stability problems associated with acid combination, such as a tendency for coloration; currently, separately produced glucose - Electrolyte preparations and amino acid preparations are mixed before use and administered to patients. Combining these two formulations into a single formulation reduces the time required for compounding at the time of use and reduces the possibility of bacterial contamination, but the biggest advantage of the combined formulation is that The problem is that the browning reaction (Maillard reaction) that occurs between sugar and amino acids in an aqueous solution causes the preparation to be easily colored, resulting in poor sterilization resistance and storage stability. As a result of various studies on preventing the above-mentioned coloring of aqueous solutions containing glucose, amino acids, and electrolytes, the present inventor found that coloring is PH-dependent, as described below, and that the higher the PH, the more likely it is to be colored. The present invention was completed after discovering that coloring varies greatly depending on the type of acid salt, and that among organic acid salts, lactate causes the least amount of coloring. That is, the present invention is an infusion solution used for complete parenteral nutrition containing glucose, amino acids and electrolytes,
In infusions using organic acid salts or mixtures of organic and inorganic acid salts as electrolytes, lactate is used as the organic acid salt, and PH is adjusted with lactic acid and/or mineral acids.
There is a method for manufacturing an infusion solution which consists of adjusting the amount of 4.5 to 5.5. The present invention will be explained in detail below. When aqueous solutions with the three compositions shown in Table 1 below are melt-sealed in an ampoule under nitrogen atmosphere and heated at 100°C for 30 or 60 minutes, the liquids with compositions A and B will be colored yellow to brown, and their strength will change. can be expressed as absorbance at 400 nm. Composition C, which contains amino acids and electrolytes but no glucose, shows almost no coloration after heating, but coloration occurs in compositions A and B, where glucose and amino acids coexist, and in particular, A, which contains electrolytes, is more markedly colored than B. .
【表】
また、下表2から明らかな如く組成AのPHを塩
酸または水酸化ナトリウムで変化させた場合、PH
が高い程、加熱後の着色が大きい。[Table] Also, as is clear from Table 2 below, when the PH of composition A is changed with hydrochloric acid or sodium hydroxide, the PH
The higher the value, the greater the coloring after heating.
【表】
また下表3から明らかな如く着色反応の促進因
子として電解質が関係していることが判つたの
で、Aの組成の成分のうち、酢酸ナトリウムの濃
度を変化させて100℃で加熱すると、着色の強さ
は酢酸ナトリウムの濃度に依存することが判つ
た。[Table] Also, as is clear from Table 3 below, it was found that electrolytes are involved as a factor promoting the coloring reaction, so among the components of composition A, the concentration of sodium acetate was changed and heated at 100℃. It was found that the intensity of coloring was dependent on the concentration of sodium acetate.
【表】【table】
【表】
塩酸 適量
pH 4.6
* 内容は表1と同じ
他の電解質の濃度を変えても、加熱による着色
の強さは変わらず同じように着色した。以上の結
果をまとめると組成Aの着色はブドウ糖とアミノ
酸によつておこり、酢酸ナトリウムが促進してい
るといえる。よつて、ブドウ糖とアミノ酸との間
の褐変反応に対する各種有機酸塩の影響を比較し
たのが下表4の結果であり、これより有機酸塩の
種類によつて着色度が大幅に変わり、試験した有
機酸塩の中では乳酸塩が最も影響が少なく、クエ
ン酸塩が最も影響が大きいといえる。[Table] Hydrochloric acid appropriate amount
pH 4.6
*Contents are the same as in Table 1 Even if the concentration of other electrolytes was changed, the intensity of coloring due to heating did not change and the coloring remained the same. To summarize the above results, it can be said that the coloration of composition A is caused by glucose and amino acids, and is promoted by sodium acetate. Therefore, the results shown in Table 4 below are a comparison of the effects of various organic acid salts on the browning reaction between glucose and amino acids, and the results show that the degree of coloring changes significantly depending on the type of organic acid salt, Among the organic acid salts affected, lactate has the least influence, and citrate has the greatest influence.
【表】
アンプル空間窒素
第1図は下記組成
ブドウ糖 18.7%(重量)
アミノ酸群* 4%
塩化ナトリウム 0.0346%
リン酸1カリウム 0.082%
硫酸マグネシウム 0.103%
塩化カルシウム 0.058%
酸性亜硫酸ナトリウム 0、00.2、00.4%
塩 酸 適量
アンプル空間窒素
*内容は表1と同じ
を有する水溶液について有機酸塩として0.0756モ
ル/の乳酸ナトリウムまたは酢酸ナトリウムを
用い、塩酸でPHを調整し、100℃で60分加熱した
ときの色調とPHの関係および酸性亜硫酸ナトリウ
ム添加の影響を示すグラフであり、これより酸性
亜硫酸ナトリウムの添加は更に着色を軽減する効
果をもつていることが判る。比較のために乳酸ナ
トリウムの代わりに酢酸ナトリウムを用いたとき
の結果を示したが、PHが高い場合に乳酸ナトリウ
ムの効果がより大きくあらわれていることがわか
る。
なお、ブドウ糖、アミノ酸、電解質を含む輸液
のPHは、第1図のPH域より低い、すなわちPH4.5
より低いと着色の点ではよい反面、液の緩衝性が
強いため、大量を静注することを考えれば生体に
とつて好ましくない。また、PHが高くなる程着色
しやすくなる傾向があることから結局望ましいPH
域は4.5〜5.5である。
以上に詳述したところから明らかなように本発
明はブドウ糖、アミノ酸およびカリウム、ナトリ
ウム、マグネシウム、カルシウム、リン酸、クロ
ールの各イオンを供給する電解質を含む輸液にお
いて、電解質で有機酸塩の形をとるものにおいて
は乳酸塩を用い、またPHを4.5〜5.5に調整するに
当つて乳酸および/または鉱酸を用い、水溶性の
亜硫酸塩または酸性亜硫酸塩またはピロ亜硫酸塩
を添加することを特徴とするものである。
以下に実施例をあげるが、何等本発明の範囲を
限定するものではない。
実施例 1
ブドウ糖 100g
塩酸アルギニン 2.7g
イソロイシン 2.5g
塩酸ヒスチジン 1.4g
ロイシン 3.0g
アミノ酢酸 4.1g
塩酸リジン 3.9g
塩化ナトリウム 0.242g
メチオニン 2.6g
リン酸1カリウム 0.574g
フエニルアラニン 1.7g
硫酸マグネシウム 0.721g
トレオニン 1.7g
塩化カルシカム 0.408g
トリプトフアン 0.9g
乳酸ナトリウム 5.6g
バリン 2.5g
酸性亜硫酸ナトリウム 0.4g
以上を注射用蒸留水700mlに溶解し、10%乳酸
を添加してPH5に調整する。蒸留水を追加して全
量1とし、ミリポアフイルターで過して500
ml輸液用バイアルに充填した後、日本薬局方一般
試験法滅菌法に準じて滅菌した。無色澄明の輸液
を得た。
実施例 2
実施例1において、PHの調整を10%乳酸に代え
てN/10−塩酸によつて行ない、PH5.5に調整し、
以下実施例1と同様に操作し、殆ど無色澄明の輸
液を得た。
実施例 3
実施例1において、塩化カルシウムに代えて乳
酸カルシウム0.857gを用いN/10−塩酸を添加
してPH5に調整する。以下実施例1と同様に操作
し、無色澄明の輸液を得た。[Table] Ampoule space nitrogen Figure 1 shows the following composition Glucose 18.7% (weight) Amino acid group * 4% Sodium chloride 0.0346% Monopotassium phosphate 0.082% Magnesium sulfate 0.103% Calcium chloride 0.058% Sodium acid sulfite 0, 00.2, 00.4% Hydrochloric acid Appropriate amount Ampoule space nitrogen This is a graph showing the relationship between pH and the effect of adding acidic sodium sulfite, and it can be seen from this that the addition of acidic sodium sulfite has the effect of further reducing coloring. For comparison, we have shown the results when sodium acetate was used instead of sodium lactate, and it can be seen that the effect of sodium lactate is more pronounced when the pH is high. Note that the PH of the infusion containing glucose, amino acids, and electrolytes is lower than the PH range shown in Figure 1, that is, PH4.5.
A lower concentration is better in terms of coloring, but the buffering properties of the solution are strong, which is not preferable for living organisms if a large amount is to be injected intravenously. In addition, the higher the PH, the easier it is to be colored, so the desired PH
The range is 4.5-5.5. As is clear from the above detailed description, the present invention provides an electrolyte in the form of an organic acid salt in an infusion containing an electrolyte that supplies glucose, amino acids, and potassium, sodium, magnesium, calcium, phosphate, and chloride ions. In addition, lactic acid and/or mineral acid are used to adjust the pH to 4.5 to 5.5, and water-soluble sulfite, acid sulfite, or pyrosulfite is added. It is something to do. Examples are given below, but they are not intended to limit the scope of the present invention in any way. Example 1 Glucose 100g Arginine hydrochloride 2.7g Isoleucine 2.5g Histidine hydrochloride 1.4g Leucine 3.0g Aminoacetic acid 4.1g Lysine hydrochloride 3.9g Sodium chloride 0.242g Methionine 2.6g Monopotassium phosphate 0.574g Phenylalanine 1.7g Magnesium sulfate 0.721g threonine 1.7g Calcicum chloride 0.408g Tryptophan 0.9g Sodium lactate 5.6g Valine 2.5g Sodium acid sulfite 0.4g Dissolve the above in 700ml of distilled water for injection, and adjust the pH to 5 by adding 10% lactic acid. Add distilled water to bring the total volume to 1, and pass through a Millipore filter to bring it to 500.
After filling into a ml infusion vial, it was sterilized according to the Japanese Pharmacopoeia General Tests Sterilization Method. A clear and colorless infusion solution was obtained. Example 2 In Example 1, the pH was adjusted to 5.5 by using N/10-hydrochloric acid instead of 10% lactic acid.
The procedure was then carried out in the same manner as in Example 1 to obtain an almost colorless and clear infusion solution. Example 3 In Example 1, 0.857 g of calcium lactate was used instead of calcium chloride, and the pH was adjusted to 5 by adding N/10-hydrochloric acid. The procedure was then carried out in the same manner as in Example 1 to obtain a colorless and clear infusion solution.
第1図は輸液における乳酸ナトリウムおよび酢
酸ナトリウムとPHの関係、および酸性亜硫酸ナト
リウム塩添加の影響を示すグラフである。
FIG. 1 is a graph showing the relationship between sodium lactate and sodium acetate in infusions and pH, and the influence of addition of acidic sodium sulfite salt.
Claims (1)
ウム、ナトリウム、マグネシウム、カルシウム、
リン、クロールの各イオンを供給する塩を含む完
全静脈栄養輸液であつて、電解質として有機酸
塩、または有機酸塩と無機酸塩の混合物を用いた
輸液において、有機酸塩として乳酸塩を使用し、
更に水溶液中で亜硫酸イオンを形成する塩を添加
し、乳酸および/または鉱酸でPHを4.5〜5.5に調
整することを特徴とする輸液の製造法。1 Glucose, amino acids and electrolytes such as potassium, sodium, magnesium, calcium,
Total parenteral nutrition infusions containing salts that supply phosphorus and chloride ions, using lactate as the organic acid salt in infusions that use organic acid salts or a mixture of organic and inorganic acid salts as electrolytes. death,
A method for producing an infusion solution, which further comprises adding a salt that forms sulfite ions in an aqueous solution, and adjusting the pH to 4.5 to 5.5 with lactic acid and/or mineral acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57050540A JPS58167516A (en) | 1982-03-29 | 1982-03-29 | Preparation of sugar, amino acid and electrolytic transfusion solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57050540A JPS58167516A (en) | 1982-03-29 | 1982-03-29 | Preparation of sugar, amino acid and electrolytic transfusion solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58167516A JPS58167516A (en) | 1983-10-03 |
JPH026335B2 true JPH026335B2 (en) | 1990-02-08 |
Family
ID=12861837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57050540A Granted JPS58167516A (en) | 1982-03-29 | 1982-03-29 | Preparation of sugar, amino acid and electrolytic transfusion solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58167516A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6130523A (en) * | 1984-07-23 | 1986-02-12 | Terumo Corp | Transfusion solution containing reducing sugar, branched amino acid and electrolyte |
JPS6178719A (en) * | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | Composite transfusion |
JPS62221621A (en) * | 1986-03-24 | 1987-09-29 | Tanabe Seiyaku Co Ltd | Complex transfusion solution |
JPH06312923A (en) * | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | Nutrient infusion solution for peripheral venous nutrition |
JP5309404B2 (en) | 2008-05-02 | 2013-10-09 | 株式会社林原 | Method for inhibiting coloring of syrup-like sweetener containing non-reducing oligosaccharide having β-fructofuranoside bond and reducing sugar and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5235729A (en) * | 1975-09-16 | 1977-03-18 | Sumikura Kogyo Kk | Opening part detecting device |
JPS5344616A (en) * | 1976-10-01 | 1978-04-21 | Takeda Chem Ind Ltd | Injections |
JPS555007A (en) * | 1978-06-23 | 1980-01-14 | Hitachi Ltd | Circuit for preventing abnormal voltage |
JPS5549567A (en) * | 1978-10-03 | 1980-04-10 | Textron Inc | Internal combustion engine |
JPS5550007A (en) * | 1978-10-05 | 1980-04-11 | Idemitsu Kosan Co Ltd | Preparation of modified polypropylene resin |
-
1982
- 1982-03-29 JP JP57050540A patent/JPS58167516A/en active Granted
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5235729A (en) * | 1975-09-16 | 1977-03-18 | Sumikura Kogyo Kk | Opening part detecting device |
JPS5344616A (en) * | 1976-10-01 | 1978-04-21 | Takeda Chem Ind Ltd | Injections |
JPS555007A (en) * | 1978-06-23 | 1980-01-14 | Hitachi Ltd | Circuit for preventing abnormal voltage |
JPS5549567A (en) * | 1978-10-03 | 1980-04-10 | Textron Inc | Internal combustion engine |
JPS5550007A (en) * | 1978-10-05 | 1980-04-11 | Idemitsu Kosan Co Ltd | Preparation of modified polypropylene resin |
Also Published As
Publication number | Publication date |
---|---|
JPS58167516A (en) | 1983-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4604286A (en) | Infusion solution for parenteral nutrition | |
KR890002948B1 (en) | Method for preventing browning of an infusion solution | |
RU2260429C9 (en) | Sodium chloride-containing moxifloxacin compositions | |
JPS6025918A (en) | Aqueous solution containing fat-soluble drug | |
FI78837C (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN FOER INJEKTIONSADMINISTRATION LAEMPLIG, STABIL OCH SALTSYRAHALTIG VATTENLOESNING AV CIS-PLATINA. | |
JPS6021570B2 (en) | Method for manufacturing high concentration preparations of DOPAs | |
KR970000507B1 (en) | Stabilized anthracycline preparation | |
JPH026335B2 (en) | ||
JP3146218B2 (en) | Eye drops | |
JPH0670718A (en) | Nutrient composition | |
JPH027575B2 (en) | ||
NO322334B1 (en) | Lyophilized preparation of human bone morphogenetic factor MP52, and method of preparing a lyophilized preparation of human bone morphogenetic factor MP52 | |
JPS59181223A (en) | Stabilization of interferon | |
JP2720165B2 (en) | Glucose electrolyte compounding agent | |
JP2006001945A (en) | Vitamin b1-formulated comprehensive transfusion for peripheral intravenous administration | |
JPH1087497A (en) | Peripheral intravenous transfusion solution | |
JP3711400B2 (en) | Infusion preparation | |
EP0334551B1 (en) | Anti-neoplastic formulations | |
JP2003055195A (en) | Vitamin b1-formulated comprehensive transfusion for peripheral intravenous administration | |
JPS6130522A (en) | Preparation of transfusion solution containing saccharide, amino acid and electrolyte | |
JPH0414646B2 (en) | ||
JPS63179827A (en) | Stable drug containing adenosine triphosphate and magnesium ion | |
JPH0585930A (en) | Lyophilized preparation of vitamin | |
JPS63130536A (en) | Production of stable cocarboxylase lyophilized preparation | |
JP3208166B2 (en) | Stabilization method for amino acid-containing infusion |